Sørensen J B, Bach F, Dombernowsky P, Hansen H H
Department of Oncology, Finsen Institute/Rigshospitalet, Copenhagen, Denmark.
Cancer Chemother Pharmacol. 1991;27(6):487-9. doi: 10.1007/BF00685166.
A total of 26 evaluable patients with previously untreated, non-resectable adenocarcinoma of the lung were given 80 mg/m2 i.v. teniposide daily for 5 days every 3 weeks. Three partial responses (11%) were obtained that lasted for 12, 11 and 32 weeks, respectively. Leucopenia was the dose-limiting side effect, with WBC counts of less than 2 x 10(9)/l being observed in 42% of patients, resulting in one septic death. At the dose and schedule used in the present study, teniposide showed only limited activity in adenocarcinoma of the lung.
总共26例先前未经治疗的不可切除的肺腺癌可评估患者，每3周静脉注射替尼泊苷80mg/m²，每日1次，连用5天。获得了3例部分缓解（11%），缓解分别持续了12周、11周和32周。白细胞减少是剂量限制性副作用，42%的患者白细胞计数低于2×10⁹/L，导致1例败血症死亡。在本研究使用的剂量和给药方案下，替尼泊苷在肺腺癌中仅显示出有限的活性。
